National registry for pediatric inflammatory brain diseases in Switzerland

Swiss Pediatric Inflammatory Bain Disease Cohort Study

Observational University of Bern · NCT05017142

This study is collecting information on children with inflammatory brain diseases in Switzerland to see how to better diagnose and treat these conditions.

Quick facts

Study typeObservational
Enrollment500 (estimated)
AgesN/A to 36 Years
SexAll
SponsorUniversity of Bern Academic / other
Locations13 sites (Aarau, Canton of Aargau and 12 other locations)
Trial IDNCT05017142 on ClinicalTrials.gov

What this trial studies

The Swiss Pediatric Inflammatory Brain Disease Registry collects comprehensive data on pediatric patients diagnosed with inflammatory brain diseases, including conditions like optic neuritis and multiple sclerosis. Implemented in 2020, it aims to improve diagnosis, treatment, and management of these conditions through systematic data collection across multiple centers in Switzerland. The registry facilitates research and enhances collaboration among clinicians and researchers, ultimately striving to optimize healthcare and quality of life for affected children.

Who should consider this trial

Good fit: Ideal candidates include pediatric patients diagnosed with specified inflammatory brain diseases before the age of 18 and living or being treated in Switzerland.

Not a fit: Patients diagnosed with inflammatory brain diseases after the age of 18 or those not residing in Switzerland may not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could lead to improved diagnosis and treatment strategies for children with inflammatory brain diseases.

How similar studies have performed: Other national registries for similar conditions have shown success in improving patient outcomes and understanding disease epidemiology.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

All patients living and/or treated in Switzerland with an IBrainD specified in the following list diagnosed from 2005 onward and with a disease onset before the age of 18.

* Written informed consent by patients (and/or legal representative(s), if applicable)
* Optic Neuritis
* Transverse Myelitis
* Acute disseminated encephalomyelitis
* Multiple Sclerosis
* Neuromyelitis Optica Spectrum Disorders
* Myelin oligodendrocyte glycoprotein antibody-associated disease
* Anti-NMDA-R Encephalitis
* Anti-GAD65 Associated Autoimmune Encephalitis
* Anti-AMPAR-1/2 Associated Autoimmune Encephalitis
* Anti-Lgi-1 Associated Autoimmune Encephalitis
* Anti-CASPR-2 Associated Autoimmune Encephalitis
* Anti-GABAR-1/2 Associated Autoimmune Encephalitis
* Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis
* Hashimoto Encephalopathy
* CNS Vasculitis
* CNS Sarcoidosis
* CNS Lupus
* Rasmussen Encephalitis

Exclusion Criteria:

* Neurological symptoms due to infectious diseases of the CNS
* Genetic/metabolic causes of central demyelinating diseases
* Neurological symptoms due to Guillain-Barré-Syndrome

Where this trial is running

Aarau, Canton of Aargau and 12 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Optic NeuritisTransverse MyelitisAcute Disseminated EncephalomyelitisMultiple SclerosisNeuromyelitis Optica Spectrum DisorderAnti-NMDAR EncephalitisAnti-GAD65 Associated Autoimmune EncephalitisAnti-AMPAR-1/2 Associated Autoimmune Encephalitis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.